Gentherm raises FY2026 guidance, receives FDA clearance for ThermAffyx medical device

Here is the rewritten news content as clean, well-structured English Markdown.

Publication Date: July 24, 2026, at 1:45 PM UTC

Gentherm (THRM) Q2 2026 Earnings Call Transcript

Source: Motley Fool Transcribing, The Motley Fool Date: Fri, July 24, 2026, at 6:45 AM PDT Read Time: 26 minutes

• Ticker: THRM

Date of Call

Thursday, July 23, 2026, at 8:00 a.m. ET

Call Participants

• Gregory Blanchette – Senior Director of Investor Relations
• William Presley – President and Chief Executive Officer
• Jonathan Douyard – Chief Financial Officer

Full Conference Call Transcript

Operator: Greetings, and welcome to Gentherm's Second Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note that this conference is being recorded. I will now turn the conference over to Gregory Blanchette, Senior Director of Investor Relations. Thank you. You may begin.

Gregory Blanchette: Thank you, and good morning, everyone. Thanks for joining us today.

Gentherm's earnings results were released earlier this morning, and a copy of the release is available at gentherm.com. Additionally, a webcast replay of today's call will be available later today on the Investor Relations section of Gentherm's website.

During this call, we will make forward-looking statements within the meaning of federal securities laws. These statements reflect our current views with respect to future events and financial performance, and actual results may differ materially. We undertake no obligation to update them, except as required by law.

Please see Gentherm's earnings release and its SEC filings, including the latest 10-K and subsequent reports, for discussions of our risk factors and other significant assumptions, risks, and uncertainties underlying such forward-looking statements.

During the call, we will also discuss non-GAAP financial measures as defined by SEC Regulation G. Reconciliations of these non-GAAP financial measures to the comparable GAAP financial measures are included in our earnings release and investor presentation.

On the call with me today are Bill Presley, President and Chief Executive Officer, and Jon Douyard, Chief Financial Officer. During their comments, they will be referring to a presentation deck available on the Investors section of Gentherm's website.

After the prepared remarks, we will be pleased to take your questions. Now, I would like to turn the call over to Bill.

William Presley: Thank you, Greg, and good morning, everyone.

Let's begin on Slide 3 for an update on our business and the market.

Strong commercial execution, where we continue to significantly outperform the market, combined with operational discipline, resulted in an excellent first half, positioning Gentherm to deliver a solid year. Based on this performance, we are raising our full-year 2026 guidance.

We continue to monitor the macroeconomic and geopolitical environment. At the same time, we are proactively managing inflationary pressures through disciplined commercial actions and operational execution.

As we look ahead, our priorities remain clear. We are focused on executing our strategy, capitalizing on the opportunities within our control, and driving sustainable profitable growth for our shareholders.

Strategic profitable growth is a cornerstone of our strategy, and we continue to achieve critical milestones that position us for long-term success. We have confidence that Gentherm's automotive business will grow over market, while we continue to build momentum beyond the light vehicle market.

During the quarter, Gentherm products were selected by two leading North American-based furniture brands in the home and office market. In less than a year, we have successfully deployed our core technologies with five new customers and have visibility to $50 million to $100 million of revenue in this market by 2028. This is a strong proof point that our technology platforms are readily transferable beyond automotive and that we are moving with speed to capture these opportunities.

In the medical market, we remain focused on refreshing the product portfolio and expanding our customer commercial channels. I am pleased to announce that we have received FDA 510(k) clearance for ThermAffyx, an innovative new solution developed by leveraging our proven automotive technology and intellectual property. This is another powerful example of our ability to transfer differ